Internal Medicine - Gastroenterology

Medical School

Recent Grants

This grant information is supplied by the University of Michigan. Only grants received while at the University of Michigan are included.

• 1.

  Grace Su

  VA IPA Thomas Jeffreys 2013

  7/1/2013 - 9/30/2013

  Sponsor: US Dept of Veterans Affairs

• 2.

  Grace Su

  VA IPA for Binu Enchakalody 2013

  7/1/2013 - 9/30/2013

  Sponsor: US Dept of Veterans Affairs

• 3.

  Peter Higgins

  A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS OF TREATMENT WITH ORAL CNDO 201 TRICHURIS SUIS OVA SUSPENSION (TSO) AS COMPARED TO PLACEBO, FOLLOWED BY A 12 WEEK OPEN-LABEL TREATMENT PERIOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN?S DISEASE

  12/6/2012 - 12/2/2013

  Sponsor: United BioSource Corporation

• 4.

  Anna Lok

  ENtecavir Utilization, Management, and Efficacy in the United States: A MulTi-cEnter Study (ENUMERATE Study)

  12/1/2012 - 9/30/2013

  Sponsor: Bristol-Myers Squibb sourced funding through Loyola University

• 5.

  Robert Fontana

  Protocol GS-US-334-0126: A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 weeks in Subjects with Recurrent Chronic HCV Post Liver Transplant

  11/19/2012 - 10/31/2014

  Sponsor: Gilead Sciences, Inc. sourced funding through Duke University

• 6.

  William Hasler

  A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Protocol: JNJ27018966IBS3002

  11/12/2012 - 10/31/2013

  Sponsor: PPD, Inc.

• 7.

  Jonathan Dillman; Peter Higgins; Jonathan Rubin

  Contrast-Enhanced Ultrasound Assessment of Inflamed vs. Fibrotic Bowel Segments in a Crohn Disease Animal Model

  11/1/2012 - 11/1/2014

  Sponsor: Siemens Medical Solutions USA, Inc.

• 8.

  Richard Saad

  RFIB3053: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhea

  10/9/2012 - 10/8/2013

  Sponsor: Novella Clinical, Inc. sourced funding through Salix Pharmaceuticals, Inc.

• 9.

  Joel Rubenstein

  VA IPA Valbona Metko 2012-2013

  10/1/2012 - 9/30/2013

  Sponsor: US Dept of Veterans Affairs

• 10.

  Grace Su

  VA IPA for Sybil Boone 2012-2013

  10/1/2012 - 9/30/2013

  Sponsor: US Dept of Veterans Affairs

• 11.

  Grace Su

  VA IPA for Brenda Vibbart 2012-2013

  10/1/2012 - 9/30/2013

  Sponsor: US Dept of Veterans Affairs

• 12.

  Elena Stoffel

  Cancer Genomics Best Practices

  10/1/2012 - 9/30/2013

  Sponsor: US DoHHS-CMS-Subcontracts sourced funding through Michigan Department of Community Health

• 13.

  Peter Higgins

  GEM Project-A Multidisciplinary Human Study on the Genetic, Environmental and Microbial Interactions that Cause Inflammatory Bowel Disease

  10/1/2012 - 3/31/2013

  Sponsor: Crohn's and Colitis Foundation sourced funding through

• 14.

  Anna Lok

  HCV-TARGET:Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study

  9/27/2012 - 9/26/2017

  Sponsor: University of Florida

• 15.

  John Wiley; Shuangsong Hong

  Stress and Visceral Hyperalgesia: Epigenetic Mechanisms

  9/20/2012 - 8/31/2013

  Sponsor: NIH

• 16.

  John Williams

  Implementation of a pancreas knowledgebase

  9/15/2012 - 9/14/2015

  Sponsor: NIH

• 17.

  Bishr Omary

  Genetic and molecular effects on hepatocyte nucleocytoplasm protein aggregation

  9/15/2012 - 6/30/2013

  Sponsor: NIH

• 18.

  Bishr Omary

  Investing in the Future to Promote Diversity in GI Training

  9/10/2012 - 8/31/2017

  Sponsor: NIH - Subcontracts sourced funding through American Gastroenterological Association

• 19.

  Juanita Merchant

  Transcriptional Control of Gastrin

  9/1/2012 - 8/31/2017

  Sponsor: NIH

• 20.

  John Carethers; Bhramar Mukherjee

  Inflammatory Differentiation of Colorectal Cancer Among African Americans

  9/1/2012 - 8/31/2017

  Sponsor: NIH